GT Plus, Suplemento dietario complejo, repositor biológico, micronutrientes naturales no herbáceos.

• World Experiences
• Scientific Team
• Humanitarian Actions
• Frequently Asked Questions
• Evidences
• Case Review
• Contact
• 

LET YOUR FOOD BE YOUR MEDICINE, AND YOUR MEDICINE BE YOUR FOOD.
Hippocrates , IV b.c.

Researchers and development

Dr. Nathan Trainin

Born: Mendoza, Argentina, January 1, 1922
Married: Zila Degree: Profesor emérito Instituto Weizmann, M.D. (1946), Cordoba University, Argentina. ...
View complete resume

Professor Zvi Bentwich

Born: Jerusalem, Israel
Married: Tirza Degree: Professor and Head, Center for Infectious Diseases and AIDS (CIDA) Department of Virology Ben Gurion University Health Science Faculty Beer Sheba ISRAEL ...
View complete resume

Dr. Walter F. Goldman

Born: USA Degree: Master of Science (Medical Microbiology and Immunology)
Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Dr. in Medical Biology
University of Geneva Medical School, Geneva, Switzerland ...
View complete resume

CASE REVIEW META - ANALYSIS OF PACIENTS THAT RECEIVED THE CONTROLLED GIFTS

Were excluded in this document, to safeguard the privacy of patients, the details of their data, although the majority provided according to the publication. The same criterion was applied to patients who narrated their experiences. Exclusively for scientific purposes, such documentation is available to all researchers that request.

Complementary therapies are used increasingly (Eisenberg 1998; Vickers 2000). The number of essays selected at random of complementary treatments has doubled every five years (Vickers 2000), and the library of Cochrane now includes more than 100 systematical reviews of interventions in complementary medicine. Many people return to these therapies when the conventional medicine trumps them, or when they believes strongly in the efficacy of the complementary medicine. Most part of the people who lives with HIV/AIDS is using complementary medicine (Ozsoy 1999).

The increasing needs of the patients with illnesses related to the HIV provokes the response of a group of scientists that for more than 10 years have applied to the development of " Gold Train + ".
" GoldTrain + " is considered as a nutritional specific supplement, of vegetables, not herbaceous and innocuous origin that is administered by oral route.
Manufactured by means of a complex prosecution it is packed, be already in tablets, in capsules or in dust (envelopes or sachets), with skills that achieve purity supports.

OBJECTIVES

The target of this review is to determine the benefits and/or harmful effects of " Gold Train + " in patients with HIV infection or AIDS disease or of been compared to other pairs without intervention, seeking for the time passed on having finished the same one (generally to 120 days) The results of interest would be CDC classification, BMI [Body Mass Index], immune responses, digestive disorders and quality of life.

Cases analyzed

Review and metaanalysys done by Prof. Dr. Ihosvanny Gonz·lez Baez ,

Complementary therapies are being used increasingly. The number of trials of randomly selected complementary therapies has been doubled every five years, and the Cochrane Library now includes more than 100 of systematic reviews of interventions in complementary medicine. Many people return to these therapies when conventional medicine fails, or them believe strongly in the efficacy of complementary medicine. At this moment, most part of the people living with HIV / AIDS are using complementary medicine.

The growing needs of patients with HIV-related illnesses caused the response of a group of scientists who for years engaged in the development of GT + ".

GT + is considered a specific nutritional supplement, from vegetable origin, non herbal and safe, that could be orally administered.
Manufactured through a complex process, is packed with techniques that maintain its purity.

Analysis and Description of included studies

Studies (Cases Series) of survival records of patients cases (histories or summaries and analysis of the same ones), in which the nutritional supplement "GT+" had been used (intervention) with the absence of treatment, or existence of the same (antiretrovirals) were taken in consideration.

The patients included in the same ones were of both sexes and without ethnic distinction, all of them carriers of infection HIV, carriers of illnesses related to HIV and/or AIDS patient.

There were analyzed and incorporated into the review 5 studies made between 1997-2005 who are documented with the corresponding summaries of the case histories of the patients that they describe. It is a Cases Series (Regarding or Observational Cases) that received the Intervention (intaken of the nutritional supplement GT +) in different dosages and during periods of time that were corresponding to the interval of 3 to 12 months. The specific outcomes were measured earlier and after happiness.

Hardening the information of this review, were taked as Outcomes:

1. Classification of the CDC (HIV-SIDA)
2. Evolution of the BMI (Body Mass Indez).
3. Increase of CD4 lymphocytes cell count.
4. Digestive disorders (Diarrheas).
5. Life quality.
   

Tabulation and attached graphic of the information belonging to the CDC classification (Annex 1) for HIV AIDS patients, shows the quality of the sample with which the researchers worked. Most of members of the studies corresponds to the category C (63.29 %) continued by the groups A and B that had have equal distributions groups, over 18.35 %.
Let us notice that inside the group C patients are those of worse evolution, most of them in waste phase, which allows us to understand that they were patients AIDS terminal with very low numbers of lymphocytes CD4 and high viral load.

CDC Clasification

BMI behavioral analysis

Data of the related Table of this variable, shows the distribution of the BMI from-16 to 25-29.9 in the included studies. The evaluation of this information was realized taking in consideration the above mentioned index EARLIER and AFTER the correspondent intervention for every author.

It is observed as in the parameters of normality 18.5-24.9 for the sum of these patients 74.05 % of the same ones has reached a weight that locates them in the stripe: Normal weight and even over weight.

In the graphic of lines we can see the change log of each group, after intervention. Defined in the same clear trend of decline in the number of cases that are in the range criterion of low-income-infra weight (data sets related to the blue, pink and yellow lines).

However there is a trend (R ≤ = 1) in the log for the normal weight group (blue line with the dotted black) which not only demonstrates the increasing number of patients who joined this group after intervention but the potential increase at the same time later.

The following chart: Change in BMI (18.5-24.9) gives an analysis of Odd Ratio (relative risk) as the criterion for assessing the effectiveness of intervention for this group obtained with a value of 95% with OR 0.19 a confidence interval (CI) ranging from (0.12-0.29) which means that intervention is ñwithout doubt- beneficial (RR value less than 1) for the group of patients to which it was applied.

If you assume a statistical calculation of this variable to a relative risk reduction (RRR) get a 81% RRR with CI (88% - 71%) which means that 81% of the population which was administered GT + benefited from an increase in their BMI values up healthy. Also this analysis enables us to ensure that there was no risk to any weight loss or malnutrition in any of the patients who take in GT + and were included in all studies analyzed.

'

Changes in absolute CD4 lymphocytes

The following tables and graphs give us an analysis seeking the variation in CD4 lymphocytes, specifically the decline (we assume this variable negatively with intention to assess the risk for this variable in the consumption of GT +) of them after during the corresponding period of time set in each study.

The first table relates to an initial description of the total number of cases for each of the included studies and the number of patients during intake were found a decrease in the absolute value of CD4 (taken in most cases of values obtained at the end of each study), is observed in the same half of 48.7% of patients who decreased their values, it is noteworthy that these data are incorporated in both HIV + and AIDS patients (not taking into account the level of the CDC ). Against this we find that 51.3% of patients during the study period had an increase in CD4 lymphocytes which may be talking about the ability of an intervention (intake of GT+) to act as an immunomodulator.

But when you perform an analysis to discriminate between these two groups of patients (HIV +) and (AIDS) are obtained interesting results shown in the graph: Decreased Absolute CD4 vs HIV AIDS.

Data analysis defines an OR (we assume the same here as the risk to reduce CD4 lymphocites after the intake of GT +) for 0.33 with a CI (0.20 - 0.75) which is defined as a 77% benefits (increase in CD4) for AIDS patients with respect to patient HIV + (have to recall here the high number of cases in the sample are included in the CDC classification C). In this case, this would suggest us that the intake of GT + acts like an immunomodulator with much better effect (on the variable studied) in AIDS patients (including terminals) in HIV + patients (although the values show a positive effect on this group was not statistically considered significant for the same).

Evaluation of GT + effects on the diarrhea.

During the analysis of data from each study, one variable that was measured and well studied in each of them is the diarrhea. Emergence or evolution of diarrhea in patients is difficult and not clear in every particular case whether if the inclusion of this variable was defined as an adverse event to the intake of GT + or was defined -within the clinical picture of patients- as a disease associated or characteristic of the background disease. The truth is that in the analysis of this variable we were surprised by the development after 120 days of the intervention.

The chart above shows a comparison between the sign Diarrhea at the start of the intake of GT +, and what occurs 120 days later in this speech. Statistical data analysis of the relative risk for a defined variable OR (risk of having symptomatic diarrhea) of 0.39 with a CI (0.25-0.63). This would be endorsing a clear protective effect of GT+ intervention on symptom onset or maintenance.
A 61% (relative risk reduction to suffer from diarrhea) of the cases was a beneficial effect of intake of nutritional supplements to control clinical annoying signs, and it was noted that the confidence interval places this data -without any doubt- the assertion that the intake of GT + act as regulator of the digestive disorder. After GT+ intake for 120 days, this is the evidence regardless the CDC classification.

Life quality evaluation

All the studies included variables that define various methodologies for patient quality of life with questions about: daily activities, work, pain, emotional state and so on. Manner the patients responded to two basic questions that are repeated in All studies included:

How do you assess your health today? (Circle the value reported by the patient)

How do you think that your life is?

In the studies that not were conducted an graphological assessment, evaluation scales was excellent, better, equal, worse under the goal of unify the analysis understood as:
EXCELENT---------- 10-9
BETTER ------------------ 8-6
EQUAL ------------------- 5-3
WORSE -------------------- 2-0

How do you qualify your health today?

Simple observation of the data shows that the formula is inverted to 120 days, in the start up 90.38% of the cases were in a situation of 0-5 (Worst - equal) in the graph that quantifies the question against a 25.97% which was in similar situation to 120 days for assessment of the question.
If we analyze the data that correspond to the three patients who respond positively to the quality of their health, we find that the time spent evaluating the 74.04% of the sample responded in a range 10-6 (Great Best). Obtained from the statistical significance with a Chi ≤ = 5.27, df = 4 (P = 0.26). This represents the effectiveness of the intervention (GT + intake during 120 days) for the qualitative effect of the health status of patients included in the studies analyzed.

Conclusions

1. The studies included in this review consist of a Case Series and though not methodologically consistent with the gold standard for this type of work, we find a detailed description of the evolution of each patient at the time it was developed and each one care relevant to the annotation of the data included in this review.

2. The largest number of patients included in this review was in category C (C1, C2, and C3) of the CDC and we are in the presence of a sample associated with low lymphocyte levels, high viral loads and serious diseases, which is highlight as "quality" of the sample to which the intervention was applied.

3. We can say that the GT + has an apparent great effectiveness to increase the weight and BMI of more patients who ingest it (120 days) to use their label nutritional supplement even in cases of severe nutritional disorders.

4. There is an obvious possibility that the nutritional supplement GT + works as an immunomodulator to increase the absolute number of CD4 lymphocytes, this observation will require larger number of cases and other types of study designs

The contents of this website were written by Dr. Ruben Wernik Oliva